<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171003036530N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-09-03</date_registration>
      <primary_sponsor>Ardabil University of Medical Sciences</primary_sponsor>
      <public_title>Comparison the effect of IV Ibuprofen and IV Ketorolac on post operation pain.</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of efficacy and side effects of IV( intravenous) Ibuprofen and intravenous  Ketorolac in laparoscopic cholecystectomy patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30846</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: The randomization method is permuted block randomization in the individual unit. There are 90 sealed envelopes containing three types of code for example there are 30 code numbers for ibuprofen. The person in the operating room will pick an envelope for each patient without knowing the content and the drug will be administered by another person who is not aware of the drug's type, Blinding description: The randomized order of interventions was concealed in opaque individual envelopes by the staff nurse, which were later opened by the nurse in recovery room at the end of surgery. The nurse prescribed drugs(ketorolac, ibuprofen or placebo in equal volume in similar syringes) without knowing patient's ID. The patient's data was collected every six hours without knowing the type of drugs. The principal investigator, patients and outcome assessmentor were blinded to group status, knowing only randomization group codes.</study_design>
      <phase>3</phase>
      <hc_freetext>cholecystitis.</hc_freetext>
      <i_freetext>Intervention 1: The first Intervention group will receive a pain pump containing Fentanyl 100 ml and then intravenous Ketorolac 30 mg at intervals of zero, 8 and 16 hours after surgery. Intervention 2: The second Intervention group will receive a pain pump containing Fentanyl and then intravenous Ibuprofen 80 mg at intervals of zero, 8 and 16 hours after surgery. Intervention 3: Control group will receive a pain pump containing fentanyl and then intravenous Placebo at intervals of zero, 8 and 16 hours after surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be published except the patient's ID( individual documents).

When:
Get started 6 months after printing results

To whom:
Researchers working in academia or university

Conditions:
In order to use  in any type of scientific research

Where to obtain:
Email this address:sagarmehrmed@yahoo.com

How to obtain:
If the applicant send his request, after checking requested information, the data will be sent within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somaye Hoghughi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshgah Ave</address>
        <city>Ardebil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>56199-35661</zip>
        <telephone>+98 45333582779</telephone>
        <email>sagarmehrmed@yahoo.com</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Ali Mohamadian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshgah Ave</address>
        <city>Ardebil</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>56199-35661</zip>
        <telephone>+98 45 3358 2779</telephone>
        <email>sagarmehrmed@yahoo.com</email>
        <affiliation>Ardabil University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are undergoing laparoscopic cholecystectomy surgery  at Imam Khomeini Hospital in Ardebil.
Being at the age of 20 and 60 years old
Patients who accept to participate  in the research.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
History of Asthma and Pulmunary disease
History of heart disease
History of CKD (chronic kidney disease) or dialysis
History of GI (Gastrointestinal) bleeding
History of HTN (hypertension)
History of Anemia
Using Warfarin
Consumers simultaneously ACEI (angiotensin converting enzyme inhibitor) and Furosemide
Drug dependence
Allergic reaction to ibuprofen or NSAIDS or celecoxib</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>k80</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>cholecystitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first Intervention group will receive a pain pump containing Fentanyl 100 ml and then intravenous Ketorolac 30 mg at intervals of zero, 8 and 16 hours after surgery.</i_keyword>
      <i_keyword>The second Intervention group will receive a pain pump containing Fentanyl and then intravenous Ibuprofen 80 mg at intervals of zero, 8 and 16 hours after surgery.</i_keyword>
      <i_keyword>Control group will receive a pain pump containing fentanyl and then intravenous Placebo at intervals of zero, 8 and 16 hours after surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Abdominal pain. Timepoint: 6,12 ,18, 24  hours after the operation, pain will be evaluated. Method of measurement: The assessment of abdominal pain is based on the Visual Analogue Scale system.</prim_outcome>
      <prim_outcome>Shoulder pain. Timepoint: 6,12,18,24 hours after surgery. Method of measurement: The assessment of pain is based on the Visual Analogue Scale system.</prim_outcome>
      <prim_outcome>Nausea and Vomiting. Timepoint: 6,12,18,24 hours after surgery. Method of measurement: The assessment  is based on the N/V(Nausea and Vomiting)system.</prim_outcome>
      <prim_outcome>Loss of consciousness. Timepoint: 6,12,18,24 hours after surgery. Method of measurement: The assessment  is based on the Ramsay score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ardabil University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-10-02</approval_date>
        <contact_name>Ethics committee of Ardebil University of Medical Sciences</contact_name>
        <contact_address>Daneshgah Ave Ardebil Ardabil Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
